Table 2:
Demographics
| Variable | N (%) |
|---|---|
|
| |
| Age (mean +/− STD) | 30.4 +/− 8.4 |
|
| |
| Race | |
| Hispanic | 0 (0) |
| Non-Hispanic White | 39 (45.9) |
| Non-Hispanic Black | 5 (5.9) |
| Asian Pacific Islander | 0 (0) |
| American Indian | 0 (0) |
| Other | 0 (0) |
| Missing = 41 | |
|
| |
| BMI (kg/m2) | |
| <18.5 | 2 (2.4) |
| 18.5–25.0 | 22 (25.9) |
| 25.1 – 30.0 | 21 (24.7) |
| 30.1–40.0 | 32 (37.6) |
| >40.0 | 8 (9.4) |
|
| |
| Comorbidities | |
| Mental Health Diagnosis | 27 (31.8) |
| Hypothyroid | 10 (11.8) |
| Endometriosis | 7 (8.2) |
| Hypertension | 6 (7.1) |
| Hyperlipidemia | 6 (7.1) |
| Asthma | 5 (5.9) |
| Type II Diabetes | 5 (5.9) |
|
| |
| Duration of Testosterone Use | |
| 0–1 years | 22 (25.9) |
| >1 – 2 years | 27 (31.8) |
| >2 – 4 years | 16 (18.8) |
| >4 years | 20 (23.5) |
|
| |
| Type of Testosterone Used | |
| Intramuscular (IM) Cypionate | 72 (84.7) |
| Subcutaneous Cypionate | 9 (10.6) |
| IM Sustanon | 1 (1.2) |
| Transdermal | 2 (2.4) |
|
| |
| Concomitant Hormonal Use | |
| Combined oral contraceptives | 9 (10.6) |
| Depo-medroxyprogesterone | 7 (8.2) |
| Levonorgestrel 52mg | 2 (2.4) |
| Intrauterine device | 1 (1.2) |
| Missing = 76 | |
|
| |
| Ovarian Histopathology | |
| Atrophic | 3 (3.5) |
| Simple Cysts | 42 (49.4) |
| Polycystic | 5 (5.9) |
| Complex Cysts | 0 (0) |
| Endometriomas | 4 (4.7) |
| Ovarian Mass | 1 (1.2) |
| Normal Ovaries | 33 (38.8) |